With pharmacy benefits accounting for 21 cents of every health care dollar, prescription drugs are the most expensive health care benefit component. Some of those drugs are more expensive than others—a lot more expensive, as a just-released report reveals. For two years, telemedicine platform and prescription drug price tracker GoodRx has been keeping tabs on the priciest prescription drugs. Their 2020 list shows that while most of the drugs have remained the same price since last year, there are some notable changes. Daraprim, which sparked a national conversation about drug prices during the Martin Shkreli trial, is no longer on the list now that there's finally a generic on the market. Discontinued drugs Kynmaro and Viekira XR have also been removed from the list. Related: FDA approves $2.1 million gene therapy drug The only newly approved drug on the list is Qinlock, which treats gastrointestinal stromal tumor (GIST). Other new additions to the list include Korlym and Cerdelga. Qinlock ranks 14th on the list, with a list price above $30,000 a month. Cerdelga and Korlym rank 16th and 20th, respectively. GoodRx's list includes drugs that patients can get at a pharmacy and administer themselves, and is determined by tracking list price and dosing requirements. It does not include medications that must be administered by a healthcare practitioner. See our slideshow above for the top 10 most expensive drugs on the list, and click here for the full report. Read more: |
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.